Hadassah

Hadassah-Pluristem Trial Approved for Placental Cell Bone Marrow Regeneration

Monday, Feb 22 2016

The Federal Drug Administration (FDA) has approved the start of a Phase I trial with a placental-cell based therapy to mitigate acute radiation syndrome (ARS) and enhance bone marrow regeneration following a bone marrow transplant. The product, PLX-R18, was developed by Pluristem Therapeutics based on studies of Prof. Raphael Gorodetsky, head of Hadassah’s Biotechnology and Radiobiology Laboratories at the Sharett Institute of Oncology.

ARS (sometimes known as radiation toxicity or radiation sickness) is an acute lethal illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. The syndrome affects the body’s ability to form new blood cells (hematopoietic recovery).

Prof. Gorodetsky and his colleagues helped Pluristem to identify the potency of the new cell product, having conducted an extensive preclinical study at Hadassah. The preclinical findings with PLX-R18 cells (also termed PLX-RAD) were initially published in PLOS-ONE (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066549) by Prof. Raphael Gorodetsky and the development team, and they were further verified at the National Institutes of Health (NIH) and other prominent centers in the United States. The new cell product’s mechanism of action was also explored in collaboration with the Charité Univeristy Medical Center in Berlin, where its researchers revealed that PLX-R18 cells secrete a wide range of specific proteins which could trigger the resurgence of the necessary early descendants of stem cells (progenitor cells) that can differentiate to form one or more kinds of cell and support the regeneration of all blood cell lineages.

The preclinical studies paved the way for PLX-R18’s application as a new treatment for cancer patients who suffer complications following high-dose radiation and chemotherapy. “PLX-R18-based therapy,” notes Prof. Gorodetsky, “may present a breakthrough in the lifesaving treatment of acute radiation syndrome, which so far has had very limited alternative treatments. It can be anticipated that this cell therapy may serve also as a safe and easy treatment for a variety of severe hematopoietic disorders.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, May 16 2019

First of Its Kind in Israel: Cardiac Catheterization at Hadassah on Under Two-Pound Baby

A cardiac catheterization, the first of its kind in Israel, was successfully performed this week at Hadassah Hospital Ein Kerem on a fragile premature infant, weighing under two pounds.

READ MORE ›
alt_text

Wednesday, May 15 2019

How Much Do You Know About Your Liver and Hadassah’s Life-Saving Liver Treatments?

Three pounds of reddish-brown tissue tucked under the diaphragm, your liver churns out over 1,000 different types of enzymes to help you digest food, store energy, and wash out toxins

READ MORE ›
alt_text

Monday, May 13 2019

Grappling with Life Post-Trauma: Hadassah Therapist Offers Advice

As we return to normal life in the aftermath of terror attacks, whether in synagogues, churches, or other settings in our local communities, how do we cope?

READ MORE ›
alt_text

Thursday, May 9 2019

When Gender Is Ambiguous

Under the cover of darkness, an Arab family left Gaza for Hadassah Hospital Ein Kerem. Little Noor would return as little Ahmed.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More